Skip to main content
SpringerLink
Log in

Neoadjuvant Chemoradiation Versus Hyperfractionated Accelerated Radiotherapy in Locally Advanced Rectal Cancer

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Neoadjuvant therapy is increasingly used in resectable locally advanced rectal cancer. The exact role of the addition of chemotherapy is not established. We compared neoadjuvant therapy using chemoradiation (CRT) or hyperfractionated accelerated radiotherapy (HART).

Methods

Clinical, pathological, and survival data were obtained from patients with resectable stage II or III rectal cancer within 7 cm from the anal verge. A group of 50 patients was treated with a preoperative dose of 41.6 Gy of radiotherapy (RT) in two daily fractions of 1.6 Gy over 13 days immediately followed by surgery (HART). A second group of 96 patients received 45 Gy of conventionally fractionated RT in 25 daily fractions of 1.8 Gy combined with 5-fluorouracil–based chemotherapy followed by surgery within 4 to 6 weeks (CRT). Both groups were compared in terms of morbidity, pathological downstaging, local recurrence, and survival.

Results

Both groups were comparable in terms of preoperative clinicopathological variables. The mean distance from the anal verge was 5.8 cm (HART) versus 4.9 cm (CRT). Sphincter preservation was possible in 74% (HART) versus 83.5% (CRT) of patients (P = .013). The clinical anastomotic leak rate was 2% (HART) versus 2.2% (CRT). Pathological complete response was observed in 4% (HART) versus 18% (CRT) of the resected specimens (P = .002). A pelvic recurrence developed in 6% (HART) versus 4.4% (CRT) of patients (P = .98). Overall 5-year survival was 58% (HART) versus 66% (CRT) (P = .19); disease-free 5-year survival was 51% (HART) versus 62% (CRT) (P = .037).

Conclusions

Compared with preoperative HART followed by immediate surgery, preoperative CRT followed by a 6-week waiting period enhances pathological response and increases sphincter preservation rate. This could be explained by the addition of chemotherapy or the longer interval between neoadjuvant therapy and surgery. No statistically significant difference was observed in local control or overall survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIG. 1.
FIG. 2.

Similar content being viewed by others

References

  1. Glimelius B, Pahlman L. Preoperative or postoperative radiotherapy in rectal-carcinoma—a randomized multicenter trial. Lyon Chir 1991; 87:3–8

    Google Scholar 

  2. Gray R, Hills R, Stowe R, et al. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001; 358:1291–304

    Article  Google Scholar 

  3. Heald RJ, Husband EM, Ryall RDH. The mesorectum in rectal-cancer surgery—the clue to pelvic recurrence. Br J Surg 1982; 69:613–6

    Article  PubMed  CAS  Google Scholar 

  4. Enker WE, Thaler HT, Cranor ML, et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181:335–46

    PubMed  CAS  Google Scholar 

  5. Enker WE. Total mesorectal excision—the new golden standard of surgery for rectal cancer. Ann Med 1997; 29:127–33

    PubMed  CAS  Google Scholar 

  6. Ceelen W, Pattyn P. Total mesorectal excision in the treatment of rectal cancer: a review. Acta Chir Belg 2000; 100:94–9

    PubMed  CAS  Google Scholar 

  7. Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638–46

    Article  PubMed  CAS  Google Scholar 

  8. Minsky BD, Cohen AM, Enker WE, et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol 1997; 37:289–95

    Article  CAS  Google Scholar 

  9. Bosset JF, Magnin V, Maingon P, et al. Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. Int J Radiat Oncol 2000; 46:323–7

    Article  CAS  Google Scholar 

  10. Gambacorta MA, Valentini V, Morganti AG, et al. Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II–III resectable rectal cancer: a phase II study. Int J Radiat Oncol 2004; 60:130–8

    Article  CAS  Google Scholar 

  11. Hall EJ. Physical and biological basis of radiation therapy. In: Cox JD, Kian Ang K, eds. Radiation Oncology: Rationale, Technique, Results. St Louis: Mosby, 2003; 3–62

    Google Scholar 

  12. Horiot JC, Lefur R, Nguyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma—final analysis of a randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiother Oncol 1992; 25:231–41

    Article  PubMed  CAS  Google Scholar 

  13. Shimomatsuya T, Tanigawa N, Muraoka R. Proliferative activity of human tumors—assessment using bromodeoxyuridine and flow-cytometry. Jpn J Cancer Res 1991; 82:357–62

    PubMed  CAS  Google Scholar 

  14. Cutress RI, Mullee MA, Rew DA. Clinical outcome and bromodeoxyuridine derived proliferation indices in 100 colonic and rectal carcinomas. Eur J Surg Oncol 2002; 28:516–9

    Article  PubMed  CAS  Google Scholar 

  15. Terry NHA, Meistrich ML, Roubein LD, et al. Cellular kinetics in rectal-cancer. Br J Cancer 1995; 72:435–41

    PubMed  CAS  Google Scholar 

  16. Suwinski R, Taylor JMG, Withers HR. Rapid growth of microscopic rectal cancer as a determinant of response to preoperative radiation therapy. Int J Radiat Oncol 1998; 42:943–51

    Article  CAS  Google Scholar 

  17. Sebag-Montefiore D, Brown G, Rutten H, et al. An international phase II study of capecitabine, oxaliplatin, radiotherapy and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma. Interim results. Eur J Cancer 2005; 3(Suppl):170

    Google Scholar 

  18. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy—concept of additivity. Int J Radiat Oncol 1979; 5:85–91

    CAS  Google Scholar 

  19. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731–40

    Article  PubMed  CAS  Google Scholar 

  20. Nagtegaal I, Gaspar C, Marijnen C, et al. Morphological changes in tumour type after radiotherapy are accompanied by changes in gene expression profile but not in clinical behaviour. J Pathol 2004; 204:183–92

    Article  PubMed  CAS  Google Scholar 

  21. De Meerleer G, Pattyn P, Fortan L, et al. High-dose preoperative radiotherapy does not alter the strength of unilaterally irradiated colon anastomoses in rats. Int J Radiat Oncol 1999; 44:163–70

    Article  Google Scholar 

  22. El-Malt M, Ceelen W, De Meerleer G, et al. Influence of preoperative combined radiochemotherapy on surgical outcome and colonic anastomotic healing: experimental study in the rat. Int J Radiat Oncol 2001; 50:1073–8

    Article  CAS  Google Scholar 

  23. O’Leary DP, Fide CJ, Foy C, et al. Quality of life after low anterior resection with total mesorectal excision and temporary loop ileostomy for rectal carcinoma. Br J Surg 2001; 88:1216–20

    Article  PubMed  CAS  Google Scholar 

  24. Gastinger I, Marusch F, Steinert R, et al. Protective defunctioning stoma in low anterior resection for rectal carcinoma. Br J Surg 2005; 92:1137–42

    Article  PubMed  CAS  Google Scholar 

  25. Coucke PA, Sartorelli B, Cuttat JF, et al. The rationale to switch from postoperative hyperfractionated accelerated radiotherapy to preoperative hyperfractionated accelerated radiotherapy in rectal cancer. Int J Radiat Oncol 1995; 32:181–8

    CAS  Google Scholar 

  26. Voelter V, Stupp R, Matter M, et al. Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study. Int J Radiat Oncol 2003; 56:1288–94

    Article  Google Scholar 

  27. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72:15–24

    Article  PubMed  CAS  Google Scholar 

  28. Weinstein GD, Rich TA, Shumate CR, et al. Preoperative infusional chemoradiation and surgery with or without an electron-beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol 1995; 32:197–204

    CAS  Google Scholar 

  29. Sun XN, Yang QC, Hu JB. Pre-operative radiochemotherapy of locally advanced rectal cancer. World J Gastroenterol 2003; 9:717–20

    PubMed  Google Scholar 

  30. Crane CH, Skibber JM, Birnbaum EH, et al. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol 2003; 57:84–9

    Article  CAS  Google Scholar 

  31. Bouliswassif S, Gerard A, Loygue J, et al. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery—trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Cancer 1984; 53:1811–8

    Article  CAS  Google Scholar 

  32. Gerard J, Conroy T, Bonnetain F, et al. Preoperative (Preop) radiotherapy (RT) plus FU/folinic acid (FA) in T3.4 rectal cancers: preliminary results of the FFCD 9203 randomized trial. Int JRadiat Oncol 2004; 60:S138

    Article  Google Scholar 

  33. Conroy T, Bonnetain F, Chapet O, et al. Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: preliminary results of the FFCD 9203 randomized trial. J Clin Oncol 2004; 22:276s

    Google Scholar 

  34. Bosset JF, Calais G, Mineur L, et al. Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer? Report of the 22921 EORTC phase III trial. J Clin Oncol 2004; 22:246S

    Google Scholar 

  35. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol 2005; 23:5620–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium

    Wim Ceelen MD, Piet Pattyn MD, PhD & Jean-Marc Gillardin MD

  2. Department of Radiotherapy, University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium

    Tom Boterberg MD, PhD & Marc van Eijkeren MD, PhD

  3. Department of Pathology, Erasmus Hospital, Lenniksebaan 808, B-1070, Brussels, Belgium

    Pieter Demetter MD, PhD

  4. Department of Radiology, University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium

    Peter Smeets MD

  5. Department of Hepatogastroenterology, University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium

    Nancy Van Damme PhD, Els Monsaert MD & Marc Peeters MD, PhD

Authors
  1. Wim Ceelen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tom Boterberg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Piet Pattyn MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc van Eijkeren MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-Marc Gillardin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pieter Demetter MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter Smeets MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nancy Van Damme PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Els Monsaert MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marc Peeters MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wim Ceelen MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ceelen, W., Boterberg, T., Pattyn, P. et al. Neoadjuvant Chemoradiation Versus Hyperfractionated Accelerated Radiotherapy in Locally Advanced Rectal Cancer. Ann Surg Oncol 14, 424–431 (2007). https://doi.org/10.1245/s10434-006-9102-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-006-9102-0

Keywords

Search

Navigation